<DOC>
	<DOCNO>NCT00185510</DOCNO>
	<brief_summary>Purpose study : One bothering feature atopic dermatitis relapse nature . Hence , worthwhile test mode efficiently prevent relapse least increase time disease recurs . In order give recommendation patient , study scientifically describe efficacy safety give regimen , namely maintenance therapy two day week Advantan .</brief_summary>
	<brief_title>Efficacy Safety Study Advantan Maintenance Treatment Atopic Dermatitis</brief_title>
	<detailed_description>The study initially post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany . Intendis GmbH , Bayer HealthCare company , sponsor trial .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone aceponate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Acute 'Severe ' 'Very Severe ' flare atopic dermatitis ; minimum affect body surface History moderate severe form atopic dermatitis least two year Pregnancy , breast feeding Known immune , hepatic , renal insufficiency Acute herpes simplex mollusca contagiosa infection Acute severe impetigo contagiosa . A slight superinfection eczema exclusion criterion Severe viral , bacterial , fungal skin infection ( chicken pox , prominent tinea corporis ) Acute infestation ( e.g . head louse , scabies )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>